Skip to main content

Advertisement

SpringerLink
Log in

The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Our aim was to study the efficacy and safety of combination chemotherapy with gemcitabine plus cisplatin (GC) for patients with advanced urothelial carcinoma (UC) after failure of methotrexate, vinblastin, adriamycin, and cisplatin (M-VAC) chemotherapy.

Methods

We studied a total of 33 patients with advanced UC. All patients were treated with M-VAC with a mean of 3.2 courses per patient and had showed disease progression or no response. Clinical and pathological features were correlated to survival rates, and the incidence and degree of toxicities were also retrospectively reviewed.

Results

A total of 132 courses of GC with a mean of 4.0 courses per patients were undergone.

Two (6.0%) complete responses and 11 (33.3%) partial responses produced an overall response rate of 39.4%. In 55 assessable lesions, there were 2 (4%) complete responses, 13 (23%) partial responses, 31 (55%) with stable disease, and 10 (18%) with progressive disease. Overall, mean of survival time after GC chemotherapy was 10.5 months (range, 3.0–22.9 months). In univariate analysis, the patients with higher serum hemoglobin or single metastasis or no liver metastasis tended to survive longer than those with lower hemoglobin or multiple metastases or existence of liver metastasis. Although grade 3–4 neutropenia was seen in 22 patients (66.7%) and grade 3–4 thrombocytopenia was seen in 10 patients (30.3%), fatal side effects were not observed.

Conclusions

The combination chemotherapy with GC seems feasible with no severe side effects and may provide a survival benefit for patients with advanced UC after failure of M-VAC chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Sternberg CN, Yagoda A, Scher HI et al (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403–407

    PubMed  CAS  Google Scholar 

  2. Saxman SB, Propert KJ, Einhorn LH et al (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15:2564–2569

    PubMed  CAS  Google Scholar 

  3. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077

    PubMed  Google Scholar 

  4. Ozawa A, Tanji N, Ochi T et al (2007) Gemcitabine and cisplatin for advanced urothelial carcinomas: the Ehime University Hospital experience. Int J Clin Oncol 12:279–283

    Article  PubMed  CAS  Google Scholar 

  5. Connor JP, Olsson CA, Benson MC et al (1989) Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern. Urology 34:353–356

    Article  PubMed  CAS  Google Scholar 

  6. Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073

    PubMed  Google Scholar 

  7. Sternberg CN, Yagoda A, Scher HI et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer (Phila) 64:2448–2458

    Article  CAS  Google Scholar 

  8. Stadler WM, Kuzel T, Roth B et al (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394–3398

    PubMed  CAS  Google Scholar 

  9. Moore MJ, Tannock IF, Ernst DS et al (1997) Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441–3445

    PubMed  CAS  Google Scholar 

  10. Roth BJ, Dreicer R, Einhorn LH et al (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264–2270

    PubMed  CAS  Google Scholar 

  11. Lorusso V, Pollera CF, Antimi M et al (1998) A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34:1208–1212

    Article  PubMed  CAS  Google Scholar 

  12. Meluch AA, Greco FA, Burris HA et al (2001) Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 19:3018–3024

    PubMed  CAS  Google Scholar 

  13. Kaufman DS, Carducci MA, Kuzel TM et al (2004) A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 22:393–397

    Article  PubMed  CAS  Google Scholar 

  14. Fechner G, Siener R, Reimann M et al (2006) Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract 60:27–31

    Article  PubMed  CAS  Google Scholar 

  15. Matsumoto K, Irie A, Satoh T et al (2007) Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. Int J Urol 14:1000–1004

    Article  PubMed  CAS  Google Scholar 

  16. Kanai K, Kikuchi E, Ohigashi T et al (2008) Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int J Clin Oncol 13:510–514

    Article  PubMed  CAS  Google Scholar 

  17. Han KS, Joung JY, Kim TS et al (2008) Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer 98:86–90

    Article  PubMed  CAS  Google Scholar 

  18. Als AB, Sengelov L, von der Maase H (2008) Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule? Acta Oncol 47:110–119

    Article  PubMed  CAS  Google Scholar 

  19. Shimizu Y, Hasumi K (1999) Chemotherapy with consecutive low-dose CDDP combined with 5-FU for gynecologic malignancies (in Japanese). Jpn J Cancer Chemother 26:1564–1574

    CAS  Google Scholar 

  20. Dash A, JAt Pettus, Herr HW et al (2008) A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer (Phila) 113:2471–2477

    Article  Google Scholar 

Download references

Conflict of interest

No author has any conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan

    Tatsuo Gondo, Makoto Ohori, Riu Hamada, Ayako Tanaka, Naoya Satake, Hisashi Takeuchi, Jun Nakashima, Tadashi Hatano & Masaaki Tachibana

Authors
  1. Tatsuo Gondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Makoto Ohori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Riu Hamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ayako Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoya Satake
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hisashi Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jun Nakashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tadashi Hatano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masaaki Tachibana
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makoto Ohori.

About this article

Cite this article

Gondo, T., Ohori, M., Hamada, R. et al. The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen. Int J Clin Oncol 16, 345–351 (2011). https://doi.org/10.1007/s10147-011-0188-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-011-0188-4

Keywords

Search

Navigation